Altimmune's Pemvidutide: A Dual-Threat Drug Beyond Liver Disease, Undervalued by the Market

Related Articles

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

6 months ago

Altimmune's $225 Million Capital Raise: A Necessary Lifeline

4 months ago

Is the Market Overlooking These Undervalued Growth Opportunities in March 2026

5 months ago

Is the Market Finally Shifting Beyond Mega-Cap Tech

6 months ago

Category

You may also like

Stock News•5 days ago

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Structure Therapeutics reported positive clinical data for oral amylin ACCG-2671 and GLP-1 aleniglipron. Aleniglipron achieved up to 16.2% mean body weight reduction at 72 weeks with improved tolerabi...

GLP

Share

Stock News•2 months ago

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside

Helus Pharma's valuation (~$269M EV) under-credits HLP003's probability-weighted value, with a risk-adjusted implied EV of ~$1.5B if Phase 3 succeeds. The pivotal APPROACH readout in Q4 2026 sets up a...

HLP

Share

Stock News•2 months ago

Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade

Altimmune was upgraded to Buy after raising $535M to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed significant MASH resolution and fibrosis improvement, but competition rem...

ALT

Share